Karen Taraszka Hastings

10PUBLICATIONS
17CO-AUTHORS
Tumour immunologyMolecular targetsNanomedicineHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 29, 2026
MHC class II on melanoma cells regulates the anti-tumor T cell response.

|Oct 22, 2025
Structural changes from wild-type define tumor-rejecting neoantigens.

Anngela C Adams, Anne M Macy, Elizabeth S Borden

|Oct 03, 2025
Towards a transcriptomic biomarker for the classification of melanocytic neoplasms.

Elizabeth S Borden, Colin T Hastings, Nithish Prakash

|Jul 15, 2024
HCV- and HBV-mediated liver cancer converge on similar transcriptomic landscapes and immune profiles.

Elizabeth S Borden, Annika Jorgensen, Heini M Natri

|Feb 26, 2024
Distinct sets of molecular characteristics define tumor-rejecting neoantigens.

Anngela C Adams, Anne M Macy, Elizabeth S Borden

|May 14, 2022
High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition.

Anngela C Adams, Elizabeth S Borden, Anne M Macy

Pageof 2

Frequent Collaborators

5 joint publications

Elizabeth S Borden

4 joint publications

Kenneth H Buetow

4 joint publications

Melissa A Wilson

3 joint publications

Anne M Macy